puh71

PU-H71 is an effective selective HSP90 inhibitor with an IC50 of 51 nM.

ARRY-502 is a CRTH2 antagonist. Regulation of cytokine activity is important in molecularly targeted therapies for asthma.

Zelavespib formic (PU-H71 formic) is a potent Hsp90 inhibitor, exhibiting an IC50 value of 51 nM in MDA-MB-468 cells.

Zelavespib HCl is a novel Hsp90 inhibitor, a novel purine-based analog, and a radiosensitizer that may be a promising agent for CIRT. Zelavespib HCl shows antitumor activity in many preclinical models of malignancy. Zelavespib HCl has an inhibitory effect on the protein expression levels of Rad51 and Ku70, which may be associated with the double chain break repair in the homologous recombination pathway and non-homologous end-joining pathway.

PU-H71 hydrate is a potent inhibitor of heat shock protein 90 (Hsp90).